Terms: = Adult Hodgkin lymphoma AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
766 results:
1. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
[TBL] [Abstract] [Full Text] [Related]
2. Population pharmacokinetics and cd20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-hodgkin lymphoma.
Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
[TBL] [Abstract] [Full Text] [Related]
3. Polatuzumab vedotin, venetoclax, and an anti-cd20 monoclonal antibody in relapsed/refractory B-cell non-hodgkin lymphoma.
Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
[TBL] [Abstract] [Full Text] [Related]
4. Advancements in the Management of Follicular lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract] [Full Text] [Related]
5. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract] [Full Text] [Related]
6. Complete response to front-line therapies is associated with long-term survival in HIV-related lymphomas in Taiwan.
Ma WL; Liu WD; Sun HY; Sheng WH; Hsieh SM; Wu SJ; Hung CC
J Microbiol Immunol Infect; 2024 Jun; 57(3):426-436. PubMed ID: 38632022
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and Nuances of Precision Molecular Engineering for hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
8. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Brillembourg H; Martínez-Cibrián N; Bachiller M; Alserawan L; Ortiz-Maldonado V; Guedan S; Delgado J
Br J Haematol; 2024 May; 204(5):1649-1659. PubMed ID: 38362778
[TBL] [Abstract] [Full Text] [Related]
9. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
Polgarova K; Trneny M
Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
[TBL] [Abstract] [Full Text] [Related]
10. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-hodgkin lymphoma patients treated with R-CHOP.
Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
[TBL] [Abstract] [Full Text] [Related]
11. treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell lymphoma: Real-World Data Analysis.
Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
[TBL] [Abstract] [Full Text] [Related]
12. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract] [Full Text] [Related]
13. Consensus recommendations on the management of toxicity associated with CD3×cd20 bispecific antibody therapy.
Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical and pathological characteristics and prognosis analysis of gray zone lymphoma].
Liu SZ; Zong XP; Cai WZ; He HJ; Ma ZX; Li JQ; Li CX; Wu DP
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):69-73. PubMed ID: 38178771
[TBL] [Abstract] [Full Text] [Related]
15. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
Takaura K; Ando H; Ganoza ER
Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
[TBL] [Abstract] [Full Text] [Related]
16. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
[TBL] [Abstract] [Full Text] [Related]
17. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R cd20-negative transformed follicular lymphoma with
Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
[TBL] [Abstract] [Full Text] [Related]
18. Loss of cd20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
[TBL] [Abstract] [Full Text] [Related]
19. Rare primary pulmonary mucosa-associated lymphoid tissue lymphoma misdiagnosed with tuberculosis: A case report.
Gu M; Ji D; Lu Y; Ping G; Yan C
Medicine (Baltimore); 2023 Nov; 102(46):e36125. PubMed ID: 37986314
[TBL] [Abstract] [Full Text] [Related]
20. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F
Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556
[TBL] [Abstract] [Full Text] [Related]
[Next]
